Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases

Abstract Introduction ABP 501 was an adalimumab (ADA) biosimilar approved for treating immune-mediated inflammatory diseases (IMIDs) including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). In this retrospective study, we aimed to examine the treatment pattern...

Descripció completa

Dades bibliogràfiques

Autors principals:	Ran Jin, Silvia Kruppert, Florian Scholz, Isabelle Bardoulat, Khalil Karzazi, Francois Morand, Greg Kricorian, David Collier, Jonathan Kay
Format:	Artigo
Idioma:	Inglês
Publicat:	Adis, Springer Healthcare 2024-03-01
Col·lecció:	Rheumatology and Therapy
Matèries:	ABP 501 Adalimumab Arthritis, Psoriatic Arthritis, Rheumatoid Biosimilar pharmaceuticals Medication adherence
Accés en línia:	https://doi.org/10.1007/s40744-024-00647-4
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!